How Biotech Startups Use Lipid Nanoparticles Beyond mRNA

Lucas and Luna explore how biotech startups are repurposing lipid nanoparticles — the delivery technology that made mRNA vaccines possible — for gene editing, protein replacement, and cancer immunotherapy. They dive into the story of a startup called ReCode Therapeutics, which uses LNP technology to deliver mRNA to the lungs of cystic fibrosis patients, bypassing the limitations of current small-molecule drugs. The episode explains how tuning the lipid chemistry can target specific organs, and why this matters for rare genetic diseases. Lucas breaks down the key numbers: ReCode's lead candidate targets a mutation that affects 10 percent of cystic fibrosis patients, but the LNP platform could apply to dozens of other conditions. Luna asks the tough questions about manufacturing complexity and competition from viral vectors. The conversation stays grounded in the science and the business, with no hype — just a clear look at an enabling technology that's quietly becoming central to the biotech toolbox. #LipidNanoparticles #DrugDelivery #BiotechStartups #GeneTherapy #CysticFibrosis #ReCodeTherapeutics #mRNATherapeutics #TargetedDelivery #RareDisease #CancerImmunotherapy #CRISPR #Nanomedicine #BiotechBusiness #FexingoBusiness #BusinessPodcast #LifeSciences #Technology #StartupFunding Keep every episode free: buymeacoffee.com/fexingo